Regeneron Pharmaceuticals, Inc. (REGN) on Monday said that it has entered into a strategic in-licensing agreement with ...

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

The acquisition of HS-20094 enhances Regeneron’s portfolio ... studies with Regeneron’s proprietary drugs to address muscle loss and other obesity comorbidities, such as cardiovascular ...

On Monday, May 19, Regeneron Pharmaceuticals announced it had purchased most of 23andMe's assets for $256 million in cash at bankruptcy auction. The acquisition ... of a big drug company makes ...

Is Regeneron a good stock to buy now in light of a potential 23andMe acquisition ... turn all that genetic data into new blockbuster drugs. A few years before 23andMe became a publicly traded ...

Genetic testing firm 23andMe is set to be acquired by drug company Regeneron Pharmaceuticals following its bankruptcy in March, the companies announced on Monday, May 19. Regeneron purchased the ...

Regeneron Pharmaceuticals ... genetic data as part of its drug research for more than a decade, is augmenting its capabilities in a big way with the $256 million acquisition of assets from ...